First-line cytoreductive drug of choice in high risk essential thrombocythemia (ET) is currently hydroxyurea, a practice based on the results of a randomized study; second-line drugs of choice include pegylated interferon-α, busulfan and anagrelide. Anagrelide clinical trials were pioneered by the late Murray N. Silverstein (1928Silverstein ( -1998 of the Mayo Clinic whose studies led to FDA approval in March 1997. The current study represents a retrospective examination of the potential impact of anagrelide therapy on survival and disease complications in ET. 1076 patients with ET were considered (median age 58 years; females 63%); risk distribution, according to the international prognostic score for ET (IPSET), was 28% high, 42% intermediate, and 30% low. Overall (OS), myelofibrosis-free (MFFS) and thrombosis-free survival data were compared for ET patients diagnosed before and after the 1997 FDA approval date for anagrelide; a significant difference was apparent in OS (P = .006; HR 1.4, 95% CI 1.1-1.7) and MFFS (P < .001; HR 4.2, 95% CI 2.7-6.5), in favor of patients diagnosed prior to 1997; the difference was sustained during multivariable analysis that included IPSET. Similarly stratified survival data in polycythemia vera (n = 665) and primary myelofibrosis (n = 1282) showed no similar impact on survival (P = .3 and .17, respectively). The current study represents a retrospective analysis and suggests significantly decreased OS and MFFS in ET patients diagnosed after the FDA approval date of anagrelide. Whether or not anagrelide therapy was to blame for the worsening of OS and MFFS over time cannot be assumed and requires validation in a prospective study.
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| INTRODUCTION
Life-expectancy in essential thrombocythemia (ET) is shorter than expected from the age-and sex-matched control population but is significantly better than that of other myeloproliferative neoplasms (MPN), including polycythemia vera (PV) and myelofibrosis (MF), with median survival for patients younger than 60 years of age approaching 33 years. [1] [2] [3] [4] To date, drug therapy has not been shown to improve survival in ET and treatment is primarily indicated in order to prevent thrombotic complications. Accordingly, lower risk patients are managed by aspirin therapy or observation alone while cytoreductive therapy is reserved for high risk disease. 4, 5 First-line cytoreductive drug of choice in ET is currently hydroxyurea, a practice based on the results of a randomized study comparing hydroxyurea to no cytoreductive treatment 6 ; the particular study showed a statistically significant benefit for hydroxyurea therapy (thrombosis rate of 3.6% vs 24%). Second-line drugs of choice in high risk ET include pegylated interferon-α (IFN-α), busulfan and anagrelide. 5 Anagrelide clinical trials in MPN were pioneered by the late Murray N. Silverstein (1928 Silverstein ( -1998 8 Anagrelide has also been evaluated, in controlled studies, for its efficacy and safety as first-line therapy for ET 9, 10 ; the results of these studies suggested that anagrelide was not inferior to hydroxyurea, in one study, 10 but was associated with a higher incidence of arterial thrombosis, bleeding complications and fibrotic progression, in the second study. 9 These observations raised significant concerns regarding the potential of adverse survival impact, although the follow-up period of formal controlled studies were too short to accurately address the particular concern. The current study represents a retrospective examination of the potential impact of anagrelide therapy on survival and disease complication rates in ET.
| METHODS
The current study was approved by the institutional review board of the Mayo Clinic, Rochester, MN. The study population was recruited from a consecutive cohort of adult patients (age ≥ 18 years) with MPN seen at were followed for driver mutation screening. 15 Treatment data were limited to the period of referral date because of incomplete follow-up information on treatment details beyond that point. Statistical analyses were based on clinical and laboratory parameters obtained at the time of first referral to the Mayo Clinic which, in the majority of cases, coincided with or was within 1 year of diagnosis. All patients were followed from diagnosis until death or date of last follow-up or contact. Follow-up was until April 2018 and data collected via medical records or in certain cases, by directly contacting patients or their physicians. Risk-stratification was performed using the three-tiered prognostic model international prognostic score for ET (IPSET). 16 Overall survival (OS) and time-to-event curves, including MF-free survival (MFFS) and thrombosis-free survival (TFS) were prepared using the Kaplan-Meier method and compared by the log-rank test. Multivariate analyses were conducted using the Cox proportional hazard regression model. P values <.05 were considered significant. The JMP Pro 13.0.0 software package was used for all analyses (SAS Institute, Cary, NC). tures for cases diagnosed before (n = 433) and after (n = 643) the FDA approval date of anagrelide (1997) revealed the former cohort to be younger (median 57 vs 60 years; P = .003) and display higher platelet count (P < .001), higher percentage of cases with grade ≥ 2 bone marrow reticulin fibrosis (P = .002), higher incidence of abnormal karyotype (P = .03), higher percentage of cases with CALR mutations (P = .03), higher frequency of palpable splenomegaly (P < .001) and lower incidence of venous thrombosis (P = .02) ( Table 1) ; no significant difference was apparent for IPSET risk distribution (P = .14), hemoglobin level (P = .5), leukocyte count (P = .4) or serum levels of lactate dehydrogenase (LDH; P = .2) ( Table 1) . We suspect that some 
| RESULTS

| DISCUSSION
Anagrelide is an oral imidazoquinazoline derivative which inhibits platelet aggregation (via platelet anti-cyclic AMP phosphodiesterase activity), in both humans and animals, and also has a species-specific platelet lowering effect in humans. Proposed mechanisms of anagrelide action include megakaryocyte colony growth inhibition at high concenteration and drug interference with megakaryocyte maturation and platelet production, at therapeutic concenterations. [17] [18] [19] Anagrelide is effective in reducing the platelet count of MPN patients, to less than 600 000/micL, in more than 80% of previously treated and untreated patients regardless of disease subtype. 8 Whether or not this translates to reduced risk of thrombosis, compared to best available therapy, has never been demonstrated. Notable side effects of the drug include headaches and palpitations, significant anemia in about a quarter of the patients, 20 serious cardiac arrhythmias and cardiomyopathy and renal insufficiency. 21 The current study, which represents a retrospective, but otherwise unbiased comparative analysis, suggests significantly decreased OS and MFFS in ET patients diagnosed after the FDA approval date of anagrelide (1997). Because of the retrospective nature of our study, data on treatment information was truncated but revealed a higher incidence of anagrelide exposure, documented at time of referral, in patients referred between 1997 and 2017. The increased occurrence of fibrotic progression after 1997 is consistent with results of earlier prospective data that demonstrated an association between anagrelide therapy, as opposed to hydroxyurea therapy, and disease transformation into MF. 9 Regardless, whether or not anagrelide therapy was to blame for the worsening of OS and MFFS over time, observed in the current study, cannot be assumed and requires validation in a prospective study. The current study underscores the danger of endorsing new drugs for relatively indolent diseases, such as ET and PV, without follow-up information that is long enough to adequately assess safety in terms of survival and disease transformation rates.
